Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

OriginalTradeonrumor Feb. 3 at 2:28 PM

$NKTX interesting premarket …see if it’s real or pump fake

0 · Reply

OriginalTradeonrumor Feb. 2 at 2:47 PM

$NKTX it broke techs …unloading …looks like we are headed down…will catch on next leg up!

0 · Reply

canuck_trader92 Feb. 1 at 10:23 PM

$NKTX back down it goes

0 · Reply

OriginalTradeonrumor Jan. 30 at 8:44 PM

$NKTX buying a ton at 2.20

0 · Reply

OriginalTradeonrumor Jan. 30 at 4:16 PM

$NKTX I’m back to buying 2.15-2.25

0 · Reply

nightstocker15 Jan. 29 at 7:39 PM

$NKTX alright, enough consolidation here. Let’s take the next leg higher 💪🔥

0 · Reply

OriginalTradeonrumor Jan. 28 at 2:56 AM

$NKTX nice strong hold…onward and upward

1 · Reply

youbi336 Jan. 26 at 7:40 PM

$NKTX Accumulating... At least we broke the 200 EMA and held.

0 · Reply

peepthestamp Jan. 24 at 4:20 AM

$NKTX

0 · Reply

Lukey63 Jan. 23 at 6:28 PM

$NKTX We need to break $2.70 and hold it. That would appear to be very bullish.

0 · Reply

Nkarta to Participate in Evercore Healthcare Conference

Nov 22, 2025, 8:28 AM EST - 2 months ago

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Nov 10, 2025, 4:01 PM EST - 3 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Oct 30, 2025, 1:14 PM EDT - 3 months ago

Nkarta to Participate in November Investor Conferences

Oct 22, 2025, 10:07 AM EDT - 3 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Sep 2, 2025, 8:01 AM EDT - 5 months ago

Nkarta to Participate in a September Investor Conference

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Jul 23, 2025, 8:01 AM EDT - 6 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 22, 2025, 12:40 AM EDT - 7 months ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jun 6, 2025, 8:52 AM EDT - 8 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

May 15, 2025, 3:46 PM EDT - 9 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 14, 2025, 4:01 PM EDT - 9 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 8:01 AM EDT - 11 months ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 11 months ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 11 months ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 11 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 11 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 1 year ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 2 years ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 2 years ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 2 years ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 2 years ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

OriginalTradeonrumor Feb. 3 at 2:28 PM

$NKTX interesting premarket …see if it’s real or pump fake

0 · Reply

OriginalTradeonrumor Feb. 2 at 2:47 PM

$NKTX it broke techs …unloading …looks like we are headed down…will catch on next leg up!

0 · Reply

canuck_trader92 Feb. 1 at 10:23 PM

$NKTX back down it goes

0 · Reply

OriginalTradeonrumor Jan. 30 at 8:44 PM

$NKTX buying a ton at 2.20

0 · Reply

OriginalTradeonrumor Jan. 30 at 4:16 PM

$NKTX I’m back to buying 2.15-2.25

0 · Reply

nightstocker15 Jan. 29 at 7:39 PM

$NKTX alright, enough consolidation here. Let’s take the next leg higher 💪🔥

0 · Reply

OriginalTradeonrumor Jan. 28 at 2:56 AM

$NKTX nice strong hold…onward and upward

1 · Reply

youbi336 Jan. 26 at 7:40 PM

$NKTX Accumulating... At least we broke the 200 EMA and held.

0 · Reply

peepthestamp Jan. 24 at 4:20 AM

$NKTX

0 · Reply

Lukey63 Jan. 23 at 6:28 PM

$NKTX We need to break $2.70 and hold it. That would appear to be very bullish.

0 · Reply

OriginalTradeonrumor Jan. 23 at 5:39 PM

$NKTX not sure if I could have forecasted any better than I’ve done here —-I took 75% off the table once we hit 50’s …NOW heading big into $GOSS …buying a ton in the 2.70’s

0 · Reply

purplesniper Jan. 23 at 3:44 PM

$NKTX

0 · Reply

OriginalTradeonrumor Jan. 22 at 10:01 PM

$NKTX 🥳. Great set up for tomorrow …Let’s see what happens!

0 · Reply

OriginalTradeonrumor Jan. 22 at 8:45 PM

$NKTX dare I say we kiss 2.40 by end of day??

1 · Reply

OriginalTradeonrumor Jan. 22 at 3:13 PM

$ARTV $NKTX cash on hand is an overblown valuation metric in bio as it’s planned to be spent so it’s not 1:1 valuation…I think a fair value (without a catalyst ) is upper 2’s—-just one dudes opinion ——with that said we hit our head on 2.40 as I hought —I took half my holdings off the table as if you been following me I made over 20% —-if one of these days we can close over 2.40 then we should be good for 2.60-2.75 Congrats all who have aligned to my trade!

2 · Reply

BiotechValues Jan. 22 at 2:56 PM

$NKTX market starting to wake up to the fact that they have over $4/share in cash and only trading at $2, with data coming soon for both $NKTX and $ARTV (potentially validating NK in autoimmune)

1 · Reply

OriginalTradeonrumor Jan. 22 at 1:10 AM

$NKTX closed above 2.08…now we need to battle our way to and through the 2.30’s…a close over 2.40 and we clear 2.50’s /60’s pretty easily Prob won’t happen in a week but may have a shot 2 maybe 3 weeks Good news is while I’m not always right …dammit I’m way more right than wrong 🤣 scroll my history and see for yourself If anyone has a stock with a better shot at a 20% gain in 2 ish weeks ( not including the ~10% gain already made here) …let me know!!! Let’s see what happens!

0 · Reply

OriginalTradeonrumor Jan. 21 at 4:34 PM

$NKTX nice move so far today—-be good if we close above 2.08 today—-> on our road to 2.50/2.90!!! Let’s see what happens!

1 · Reply

sionist Jan. 21 at 8:40 AM

[WARNING] Watch out for @BiotechValues . $JSPR $PEPG $ACRV $NKTX pump & dump!

1 · Reply

BiotechValues Jan. 16 at 6:57 PM

$NKTX at some point this is going to run huge into data in 5 indications. Contrarian play, but that's where money is made. With $317M cash vs. $144M market cap and RA and Tang (activist pot) as top holders, I like my odds for serious upside. The way I see it, with cash into 2029, these guys will either explode up on strong data, or RA and Tang will execute a strategic transaction for the benefit of shareholders. Either way, seems like a no brainer with over $4/share in cash. Cell therapy in AI been hot lately

1 · Reply

OriginalTradeonrumor Jan. 15 at 9:13 PM

$NKTX yeah …Pharma got destroyed today so this was sector related …good time to buy!

0 · Reply

CarOrbitsMars Jan. 15 at 3:01 PM

$NKTX scarfing this up. Cash to operate for several years and news on the way.

0 · Reply

Market Cap	157.69M
Revenue (ttm)	0.00
Net Income (ttm)	-108.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	768,000
Avg Vol	754,724
Day's Range	N/A - N/A
Shares Out	71.03M
Stochastic %K	21%
Beta	0.60
Analysts	Strong Sell
Price Target	$11.80